News about "Targeted Cancer Therapy"

Ris-Rez Cuts Risk of Death by 54 Percent vs Topotecan in Relapsed SCLC in China

Ris-Rez reduced the risk of death by 54 percent versus topotecan in relapsed SCLC in China, extending median overall survival to 18.5 months versus 10.3 months with comparator.

Targeted Cancer Therapy | 15/09/2026 | By News Bureau

Roche's Divarasib Outperforms KRAS G12C Inhibitors in Phase 3 NSCLC Trial

Roche’s divarasib demonstrated superior Progression-Free Survival over approved KRAS G12C inhibitors in the phase 3 Krascendo-1 trial for previously treated advanced Non-Small Cell Lung Cancer (NSCLC).

Targeted Cancer Therapy | 02/07/2026 | By News Bureau |  150

Ranok Therapeutics Reports Promising Phase 1a Results for KRAS G12D Cancer Therapy RNK08954

Ranok Therapeutics has reported positive Phase 1a clinical data for investigational KRAS G12D inhibitor RNK08954, demonstrating encouraging response rates and tolerability in advanced solid tumor patients, including those with non-small cell lung cancer.

Targeted Cancer Therapy | 12/05/2026 | By News Bureau |  369

Nuvation Bio Secures FDA Nod for IBTROZI sNDA in ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio secures US Food and Drug Administration (FDA) acceptance of IBTROZI (taletrectinib) sNDA for ROS1-positive Non-Small Cell Lung Cancer (NSCLC), with updated response data and a target action date of January 4, 2027.

Targeted Cancer Therapy | 07/05/2026 | By News Bureau |  160

Jazz Pharmaceuticals Secures FDA Priority Review for Ziihera in First-Line HER2 plus Gastroesophageal Cancer

U.S. Food and Drug Administration accepts sBLA for Ziihera with Priority Review, backed by Phase III data showing improved outcomes in HER2-positive advanced gastric and gastroesophageal cancers.

Targeted Cancer Therapy | 29/04/2026 | By News Bureau |  218

Avacta Group doses first patient in AVA6103 trial, advances targeted cancer therapy platform

Phase I FOCUS-01 study to evaluate novel peptide-drug conjugate across four solid tumours following Euro 10 million fundraise and collaboration with Tempus AI.

Targeted Cancer Therapy | 11/04/2026 | By News Bureau |  434

Nuvalent Submits NDA to FDA for Neladalkib in Advanced ALK-Positive Lung Cancer

The investigational ALK inhibitor, backed by Phase I/II trial data, targets treatment-resistant non-small cell lung cancer and has received breakthrough and orphan drug designations.

Targeted Cancer Therapy | 08/04/2026 | By News Bureau |  174

MHRA Approves Bayer's Sevabertinib for HER2-Mutated Advanced Lung Cancer

Sevabertinib, a targeted therapy for HER2-mutated lung cancer, has been approved by the UK regulator to expand treatment options for advanced-stage patients.

Targeted Cancer Therapy | 04/04/2026 | By News Bureau |  189

GSK plc Secures Japan Orphan Drug Status for Ris-Rez in Small-Cell Lung Cancer

Japan’s health ministry grants orphan drug designation to GSK’s investigational ADC Ris-Rez for SCLC, supported by early clinical data showing durable responses in advanced-stage patients.

Targeted Cancer Therapy | 24/03/2026 | By News Bureau |  217